Kyntra Bio (KYNB) EBIT Margin (2014 - 2026)
Kyntra Bio (KYNB) posted EBIT Margin of 369.66% for Q1 2026, up 65.06% sequentially from 1058.1% in Q4 2025, and up 17506.0% YoY from N/an in Q1 2025.
Kyntra Bio (KYNB) EBIT Margin (2014 - 2026) Analysis & Trends
Kyntra Bio has reported EBIT Margin for 13 years, with the latest figure at 369.66% in Q1 2026.
- Quarterly EBIT Margin rose 17506.0% year-over-year to 369.66% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 602.14% (up 121360.0% YoY) and the FY2025 annual result came in at 712.66%, down 20485.0% from the prior year.
- EBIT Margin grew to 369.66% in Q1 2026 per KYNB's latest filing, from 1058.1% in the prior quarter.
- Over five years, EBIT Margin peaked at 128.84% in Q4 2023 and troughed at 38773.98% in Q3 2024.
- A 5-year average of 3741.95% and a median of 611.44% in 2023 frame the typical range for EBIT Margin.
- The sharpest annual moves came in 2024 and 2025: EBIT Margin plunged 3861581 bps in 2024, then soared 3827110 bps in 2025.
- Over 5 years, EBIT Margin stood at 787.52% in 2022, then soared by 116 bps to 128.84% in 2023, then plunged by 277 bps to 227.53% in 2024, then plunged by 365 bps to 1058.1% in 2025, then soared by 65 bps to 369.66% in 2026.
- According to Business Quant data, EBIT Margin over the past three periods registered 369.66%, 1058.1%, and 502.88% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.75 Bn | 130.90 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.96 Bn | 77.96 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.98 Bn | 59.80 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 56.33 Bn | 51.19 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.56 Bn | 28.25 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.32 Bn | 26.49 Bn | - | 19.75% |
| 10 | Kyntra Bio | 30.60 Mn | 30.60 Mn | 1.47 Mn | -1,192.27% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,192.27% |
| Mar 31, 2026 | -369.66% |
| Dec 31, 2025 | -1,058.10% |
| Sep 30, 2025 | -502.88% |
| Jun 30, 2025 | -894.07% |
| Mar 31, 2025 | -544.72% |
| Dec 31, 2024 | -227.53% |
| Sep 30, 2024 | -38,773.98% |
| Jun 30, 2024 | -11,602.00% |
| Mar 31, 2024 | -2,235.55% |
| Dec 31, 2023 | 128.84% |
| Sep 30, 2023 | -158.18% |
| Jun 30, 2023 | -611.44% |
| Mar 31, 2023 | -4,475.94% |
| Dec 31, 2022 | -787.52% |
| Sep 30, 2022 | -595.21% |
| Jun 30, 2022 | -262.44% |
| Mar 31, 2022 | -642.79% |
| Dec 31, 2021 | -817.51% |
| Sep 30, 2021 | 32.68% |